Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277554 | 0.96 | PTGDR2 (0.75) | PTGDR2 | |
| SCHEMBL2272170 | 0.93 | PTGDR2 (0.70) | PTGDR2 | |
| SCHEMBL1465975 | 0.92 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL2670026 | 0.90 | PTGDR2 (0.65) | PTGDR2 | |
| SCHEMBL1466406 | 0.90 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL2670014 | 0.89 | PTGDR2 (0.64) | PTGDR2 | |
| SCHEMBL1466236 | 0.88 | PTGDR2 (0.76) | PTGDR2 | |
| SCHEMBL2670024 | 0.88 | PTGDR2 (0.62) | PTGDR2 | |
| SCHEMBL3178268 | 0.88 | PTGDR2 (0.62) | PTGDR2 | |
| SCHEMBL1599841 | 0.87 | PTGDR2 (0.82) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268878-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2012-09-18 | — | — | US | disclosed |
| EP-2492268-A1 | Compounds having CRTH2 antagonist activity | Oxagen Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| EP-2046740-B1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LTD (GB) | 2012-05-23 | — | — | EP | disclosed |
| US-20110268693-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-7999119-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2011-08-16 | — | — | US | disclosed |
| US-20100035956-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| CN-101506159-A | Compounds having CRTH2 antagonist activity | OXAGEN LTD (GB) | 2009-08-12 | — | — | CN | disclosed |
| EP-2046740-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | Oxagen Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012511-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268693-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, HRH1, HRH4 | PTGDR2 122/4885 |
| US-20100035956-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, HRH1, HRH4 | PTGDR2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.